| P50 | author | David T Rubin | Q59660561 |
| P2093 | author name string | Sudarshan Paramsothy | |
| | Noa Krugliak Cleveland | |
| | Nada Zmeter | |
| P2860 | cites work | Natalizumab Induction and Maintenance Therapy for Crohn's Disease | Q22250890 |
| | Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial | Q28202504 |
| | Certolizumab pegol for the treatment of Crohn's disease | Q28236746 |
| | A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease | Q28270722 |
| | Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 |
| | Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial | Q28296771 |
| | Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data | Q31019795 |
| | Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials | Q33343338 |
| | Biosimilar medicines - their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology | Q33636715 |
| | Vedolizumab as induction and maintenance therapy for ulcerative colitis | Q34365566 |
| | Vedolizumab as induction and maintenance therapy for Crohn's disease | Q34365574 |
| | Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial | Q34574245 |
| | Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up | Q35995603 |
| | Explaining the cost of biotech therapies. | Q36562784 |
| | Biosimilar drugs : concerns and opportunities | Q37004574 |
| | Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis | Q37051515 |
| | A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study | Q37206622 |
| | A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study | Q37206628 |
| | A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis | Q37892444 |
| | Biosimilars in IBD: hope or expectation? | Q38090408 |
| | Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics | Q38150859 |
| | The challenge of indication extrapolation for infliximab biosimilars | Q38223006 |
| | Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease | Q38241449 |
| | Epidemiology and risk factors for IBD. | Q38366954 |
| | Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series | Q38432853 |
| | Biosimilars in inflammatory bowel disease: ready for prime time? | Q38514610 |
| | Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review | Q38915062 |
| | Joint position statement by “Sociedad Española de Patología Digestiva” (Spanish Society of Gastroenterology) and “Sociedad Española de Farmacología” (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease | Q39441672 |
| | Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey. | Q39823398 |
| | Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis. | Q39829049 |
| | Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study | Q39837731 |
| | Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort | Q40217926 |
| | Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States | Q40714725 |
| | Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study | Q40939952 |
| | Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. | Q40987050 |
| | Ustekinumab induction and maintenance therapy in refractory Crohn's disease | Q42514321 |
| | Biosimilar, biobetter and next generation therapeutic antibodies | Q42732007 |
| | ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). | Q44633613 |
| | Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. | Q53341834 |
| | Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center. | Q53444169 |
| | Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease | Q57220291 |
| | Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped | Q58814220 |
| | Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations | Q60609835 |
| | Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization | Q62476141 |
| | Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference | Q77626838 |
| | Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima | Q87158455 |
| P433 | issue | 12 | |
| P921 | main subject | inflammatory bowel diseases | Q917447 |
| P304 | page(s) | 741-751 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | Gastroenterology & hepatology | Q26842161 |
| P1476 | title | The Role of Biosimilars in Inflammatory Bowel Disease | |
| P478 | volume | 12 | |